Researchers Create a Potential Therapy for Deadly Breast Cancer That Has Few Treatment Options
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.
The therapy is known is MS1943. In a cancer cell line and mouse models, it degraded a protein called EZH2 that drives the growth of triple-negative breast cancer.
Research teams led by Jian Jin, PhD, Director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. They also showed that agents that inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple-negative breast cancer.
MS1943 effectively reduced EZH2 protein levels in a variety of cancer cell lines, including a triple-negative breast cancer cell line, leading to the death of these triple-negative breast cancer cells.
“Our findings suggest that EZH2 selective degraders such as MS1943 may provide an emerging therapeutic approach for the treatment of triple-negative breast cancer,” said Dr. Jin, who is also Co-leader of the Cancer Clinical Investigation Program at The Tisch Cancer Institute, Mount Sinai Professor in Therapeutics Discovery, and Professor of Pharmacological Sciences, and Oncological Sciences, at the Icahn School of Medicine at Mount Sinai. “The EZH2 selective degrader reported in this study is also an invaluable tool to test therapeutic hypotheses in other cancers.”
This research was supported in part by the grants R01CA230854 and R01CA218600 from the U.S. National Institutes of Health.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.